Brief: Fate Therapeutics Announces Interim Phase 1 Data For iPSC-derived NK Cell Programs In Relapsed/Refractory Acute Myeloid Leukemia
13/05/2021 22:19
May 13 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS ANNOUNCES ENCOURAGING INTERIM PHASE 1
DATA FOR
IPSC-DERIVED NK CELL PROGRAMS IN RELAPSED / REFRACTORY ACUTE
MYELOID LEUKEMIA
* FATE THERAPEUTICS INC - 4 OF 9 PATIENTS IN FT516
MONOTHERAPY
STUDY ACHIEVED OBJECTIVE RESPONSE WITH COMPLETE LEUKEMIC BLAST
CLEARANCE IN BONE MARROW
Source text for Eikon: ID:nGNX97yfFM
Further company coverage: FATE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview